OCUL
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025
COGT
Complete enrollment in SUMMIT Part 2 in the second quarter of 2025 and deliver top-line results by the end of 2025.
GPCR
Topline data from the ACCESS and ACCESS II studies are expected in the fourth quarter of 2025.
ELDN
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025
CGEM
Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025
KYMR
It will also advance the candidate in a phase lb study in AD patients in the second quarter of 2025 and report data in the fourth quarter of the year.
